Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
about
Improving quality of care in inflammatory bowel disease: what changes can be made today?Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseasesAdalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement.Diagnosis and management of intestinal Behçet's disease.Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's diseaseLong-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab.Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease.Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study.Targeting TNF-α for the treatment of inflammatory bowel disease.Future directions in inflammatory bowel disease management.anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.Adalimumab in the treatment of immune-mediated diseases.An update on medical management on Crohn's disease.Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.Early histological findings may predict the clinical phenotype in Crohn's colitis.Mucosal Healing in Clinical Practice: A Single-Center Pediatric IBD Experience.Top-down approach to biological therapy of Crohn's disease.Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort StudyClinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes.The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial.Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.Optimization of biologic therapy in Crohn's disease.Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab.How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohort.An index with improved diagnostic accuracy for the diagnosis of Crohn's disease derived from the Lennard-Jones criteria.Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.[Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?].
P2860
Q26859105-205FF183-0E5E-4AD6-ADEE-BE3E87B90D87Q27008246-3B7CB9CA-67E1-4A52-9347-A94CCFC84079Q30679247-96119676-E4AB-4042-96A7-C0B982A60542Q33562796-AE63D387-EC33-4D7C-A4DB-46F5F7DE42DCQ33681591-36BDA603-4041-49F9-8F25-5D2C3D6BCC9DQ36089928-DFE4B57B-260B-49B1-A4E0-E50EBB126535Q36847655-A4EAA597-FB67-44BF-B091-6492F00BDD2CQ36889586-BB76588C-1ED3-4567-912A-45C8C8164A3DQ37081907-C4A4C7F0-5612-4649-944F-B00992E0BB9BQ37223472-69B804F0-68C8-4FD7-AD91-203305B66600Q37521805-DAC8F5BD-9F0D-4DCF-8219-AD2C55C1F3C6Q37703514-9924C4B2-566B-4366-AC46-56A0127078BDQ38109019-700857AA-D9E4-46AB-AD2C-3ABF7BD86B95Q38160905-DAF0E44E-24D5-46F3-9EE2-6CD3B93F1EF8Q38205305-F8C74A6B-135D-4467-A09E-D17965A55C3AQ38207759-2E755819-F268-4E65-AB77-8C04F56D9DABQ38207760-1E4DBFD2-1FBD-465E-8948-2C15DB628E21Q38270674-C4206532-59EB-4E2D-90E2-1BE2DA8AA401Q38549995-023E6E0D-86C3-4043-BC02-5E14574D980EQ38621241-A24E7E48-CB1C-4550-9BA7-F53FFC154AF0Q38712270-4A889504-BF40-4A83-9202-58BCC3CAE463Q38764671-C684AD63-7346-4CD9-95E0-EB6FB6485C0DQ38895960-AB266B79-B9E9-43AC-A7D3-E9A4060B99B0Q39538749-88360370-ED6C-4220-9631-C47000FA4D68Q39797507-B42EB6D0-7D06-48A8-B8AB-D918041D5622Q40703329-98A85A7C-D0E9-4313-ADEE-7689F7E02A33Q42375893-E8B57AAB-2D67-4257-B978-81F855BFF1A1Q44290283-52CBE4B9-0C81-4402-9247-CFDCCC38596EQ47389870-341F7E4C-6671-41CB-944E-B51BB4CDCE3BQ48265479-EE950081-37E0-43AE-B17C-FAC75F704C4BQ49500732-8E510646-BED0-4D1C-BC9D-486A96603754Q51058515-6469641E-EDD4-4B61-8720-65FB31F479F9Q53052438-F82E6742-B7C0-4F39-BC22-F7F913C80D57Q53572128-91DBCF79-A152-4185-AC7D-2CDCEFEDA85BQ53665154-6B4336AF-D043-4366-9EF9-A4F86599B570
P2860
Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Subgroup analysis of the place ...... ts with early Crohn's disease.
@en
Subgroup analysis of the place ...... ts with early Crohn's disease.
@nl
type
label
Subgroup analysis of the place ...... ts with early Crohn's disease.
@en
Subgroup analysis of the place ...... ts with early Crohn's disease.
@nl
prefLabel
Subgroup analysis of the place ...... ts with early Crohn's disease.
@en
Subgroup analysis of the place ...... ts with early Crohn's disease.
@nl
P2093
P2860
P921
P1476
Subgroup analysis of the place ...... ts with early Crohn's disease.
@en
P2093
A M Robinson
D W Hommes
J F Colombel
P F Pollack
S Schreiber
W Reinisch
P2860
P304
P356
10.1016/J.CROHNS.2012.05.015
P577
2012-06-16T00:00:00Z